Product
lonigutamab
1 clinical trial
1 indication
Indication
Graves' DiseaseClinical trial
A Phase 1/2, Adaptive, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of Lonigutamab in Subjects With Thyroid Eye Disease (TED)Status: Recruiting, Estimated PCD: 2024-10-01